Loading clinical trials...
Loading clinical trials...
Using Cardiovascular Magnetic Resonance Identified Scar as the Benchmark Risk Indication Tool for Implantable Cardioverter Defibrillators in Patients With Non-Ischemic Cardiomyopathy and Severe Systolic Heart Failure
BRITISH is a UK multicentre trial of patients who have been diagnosed with heart failure due to Non-Ischemic Cardiomyopathy (NICM, or heart failure that is not caused by blocked heart arteries. Participants will be randomised into two groups. Half the participants will receive an Implantable Cardioverter-Defibrillator (ICD) and the other half will not. The aim of the study will be to compare all-cause mortality (death from any cause) between these two groups at 36 months, and longer-term to 10 years. The study has the potential to change international heart failure treatment guidelines and to improve how patients with this condition are managed.
Patients with Non-Ischemic Cardiomyopathy (NICM) have a higher risk of experiencing serious abnormal heart rhythms that might be life-threatening. Current guidelines recommend fitting a device that can correct these serious heart rhythms (Implantable Cardioverter-Defibrillator (ICD)). However, research studies have shown that 90% of patients who have an ICD will never use it because they won't experience any serious heart rhythms. A recent large trial (DANISH) of over one thousand patients with severe Non-Ischemic Cardiomyopathy has called the current guidelines into question. The trial concluded that for patients who received an ICD, there was no difference in the likelihood of dying when compared to patients that didn't have an ICD fitted. As a result, many doctors are choosing not to implant an ICD in patients with this type of heart failure, as they believe there is no overall survival benefit. However, there are clues that some patients with NICM may still benefit from an ICD, even though the headline results suggest they are not necessary. It's likely that it's the patients who are at increased risk of having a serious abnormal heart rhythm that stand to benefit from ICDs. But having an ICD fitted carries with it a significant risk of problems developing e.g. bleeding, infection, lead problems, and inappropriate shocks. These risks may not outweigh the benefits and it is this question which BRITISH will address. The study will randomly assign (like the toss of a coin), half the study participants to receive an ICD and the other half to no ICD. Both groups will be followed up to decide whether having an ICD fitted reduces the chances of dying.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Wycombe Hospital
High Wycombe, Buckinghamshire, United Kingdom
Derriford Hospital
Plymouth, Devon, United Kingdom
Royal Bournemouth Hospital
Bournemouth, Dorset, United Kingdom
Durham & Darlington NHS Foundation Trust
Darlington, Durham, United Kingdom
Royal Sussex County Hospital
Brighton, East Sussex, United Kingdom
Essex Cardiothoracic Centre
Basildon, Essex, United Kingdom
James Paget University Hospitals NHS FT
Gorleston-on-Sea, Great Yarmouth, United Kingdom
Portsmouth Hospitals University NHS Trust
Portsmouth, Hampshire, United Kingdom
Southampton Clinical Trials Unit
Southampton, Hampshire, United Kingdom
University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, United Kingdom
Start Date
April 12, 2023
Primary Completion Date
October 1, 2026
Completion Date
April 1, 2036
Last Updated
March 5, 2026
2,504
ESTIMATED participants
Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronisation Therapy Defibrillator (CRTD)
DEVICE
Lead Sponsor
University Hospital Southampton NHS Foundation Trust
Collaborators
NCT07191730
NCT07484009
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions